ZPDH:F:F-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 40.37

Change

+0.06 (+0.15)%

Market Cap

USD 0.40B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 116.19B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 109.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.25 (-0.44%)

USD 98.97B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.04 (-0.27%)

USD 63.27B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.45 (-0.19%)

USD 52.42B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.41 (+0.38%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.06 (-0.85%)

USD 38.52B
0ZC:F Zscaler Inc

+7.40 (+4.31%)

USD 37.92B

ETFs Containing ZPDH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.31% 56% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.31% 52% F 52% F
Trailing 12 Months  
Capital Gain 9.60% 56% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.60% 52% F 51% F
Trailing 5 Years  
Capital Gain 54.17% 79% B- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.17% 79% B- 57% F
Average Annual (5 Year Horizon)  
Capital Gain 12.57% 78% C+ 71% C-
Dividend Return 12.57% 76% C+ 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.88% 63% D 88% B+
Risk Adjusted Return 115.45% 98% N/A 98% N/A
Market Capitalization 0.40B 58% F 46% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike